BioCentury | Apr 24, 2020
Product Development

Sanofi sets MS submission goals for Principia-partnered Btk inhibitor, details Phase II data

Two months after Sanofi announced plans to send its oral multiple sclerosis therapy into Phase III testing, the company unveiled the detailed Phase IIb data from recurring MS patients driving the Btk inhibitor’s clinical advancement....
BioCentury | Feb 9, 2019
Product Development

Merck KGaA's large-scale partnering

Merck KGaA's deal with GlaxoSmithKline plc to develop cancer therapy M7824 enables Merck to pursue a more ambitious development plan than it could have done by going it alone, and provides a template for how...
BC Week In Review | Oct 12, 2018
Clinical News

Phase II data for Merck's Btk inhibitor highlighted at ECTRIMS

Merck KGaA (Xetra:MRK) reported 24-week data from a Phase II trial to treat relapsing multiple sclerosis showing that evobrutinib (M2951) reduced the mean total number of gadolinium-enhancing T1 lesions by up to 2.7 over placebo....
BC Extra | Oct 12, 2018
Clinical News

Phase II data for Merck's Btk inhibitor highlighted at ECTRIMS

Merck KGaA (Xetra:MRK) reported 24-week data from a Phase II trial to treat relapsing multiple sclerosis showing that evobrutinib (M2951) reduced the mean total number of gadolinium-enhancing T1 lesions by up to 2.7 over placebo....
BC Week In Review | Mar 9, 2018
Clinical News

Merck's evobrutinib meets in Phase IIb for MS

Merck KGaA (Xetra:MRK) said evobrutinib (M2951, MSC2364447C) met the primary endpoints of reducing the total number of gadolinium-enhancing T1 lesions from baseline to weeks 12, 16, 20 and 24 vs. placebo in a Phase IIb...
BC Week In Review | Nov 10, 2017
Company News

Sanofi gets rights to Principia's Btk inhibitor for MS

Principia Biopharma Inc. (South San Francisco, Calif.) said it will grant Sanofi (Euronext:SAN; NYSE:SNY) exclusive, worldwide rights to develop and commercialize PRN2246, a Bruton's tyrosine kinase (Btk) inhibitor, to treat multiple sclerosis and other undisclosed...
BC Extra | Nov 9, 2017
Company News

Sanofi gets rights to Principia's Btk inhibitor for MS

Principia Biopharma Inc. (South San Francisco, Calif.) will grant Sanofi (Euronext:SAN; NYSE:SNY) exclusive, worldwide rights to develop and commercialize PRN2246, a Bruton's tyrosine kinase (Btk) inhibitor, to treat multiple sclerosis and other undisclosed CNS diseases....
BioCentury | Nov 23, 2015
Strategy

More with less

With 16 months under his belt as the new head of global R&D for Merck KGaA's biopharmaceuticals division, Luciano Rossetti has pruned the pipeline, accelerated the unit's cancer immunotherapy efforts and revived one late-stage program....
Items per page:
1 - 8 of 8